9月25日，富士莱涨0.24%，成交额4360.92万元。两融数据显示，当日富士莱获融资买入额372.18万 元，融资偿还356.26万元，融资净买入15.92万元。截至9月25日，富士莱融资融券余额合计7499.66万 元。 责任编辑：小浪快报 截至9月19日，富士莱股东户数1.10万，较上期减少4.22%；人均流通股3088股，较上期增加4.40%。 2025年1月-6月，富士莱实现营业收入2.24亿元，同比增长3.36%；归母净利润4307.66万元，同比增长 12430.96%。 分红方面，富士莱A股上市后累计派现1.53亿元。近三年，累计派现1.16亿元。 机构持仓方面，截止2025年6月30日，富士莱十大流通股东中，银河医药混合A（011335）、银河康乐 股票A（519673）退出十大流通股东之列。 融资方面，富士莱当日融资买入372.18万元。当前融资余额7499.66万元，占流通市值的6.10%，融资余 额超过近一年70%分位水平，处于较高位。 融券方面，富士莱9月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量0.00股，融券余额0.00元，超 ...

Core Viewpoint - The company reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong operational performance and growth in key product sales [1] Financial Performance - The company achieved a revenue of approximately 307 million yuan, representing a year-on-year growth of 17.59% [1] - The net profit attributable to the parent company was around 107 million yuan, reflecting a year-on-year increase of 57.61% [1] - The net profit excluding non-recurring gains and losses was approximately 93 million yuan, which is a 75.45% increase compared to the same period last year [1] Operational Drivers - The increase in revenue was primarily driven by higher sales volumes of core products ARA and algal oil DHA [1] - Profit growth was attributed to the rise in revenue, improved production efficiency, and optimization of product and customer structures, enhancing the company's profitability [1]